Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Non Operating Income (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Non Operating Income for 15 consecutive years, with -$95.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 91.05% to -$95.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $35.0 million, a 295.72% increase, with the full-year FY2025 number at $35.0 million, up 295.69% from a year prior.
  • Non Operating Income was -$95.0 for Q4 2025 at PharmaCyte Biotech, up from -$121.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $22.2 million in Q1 2025 to a low of -$72142.0 in Q2 2022.
  • A 5-year average of $2.6 million and a median of $192.5 in 2021 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: tumbled 209.95% in 2021, then skyrocketed 8792083.4% in 2025.
  • PharmaCyte Biotech's Non Operating Income stood at $480.0 in 2021, then surged by 91173.54% to $438113.0 in 2022, then tumbled by 100.42% to -$1849.0 in 2023, then surged by 42.56% to -$1062.0 in 2024, then soared by 91.05% to -$95.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Non Operating Income are -$95.0 (Q4 2025), -$121.0 (Q3 2025), and $12.8 million (Q2 2025).